Alvogen and Reddy’s Cleared Over US Rivals To Suboxone

 
• By Aidan Fry

Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.

Suboxone
Generic rivals to Idivior's Suboxone Film from Alvogen and Dr Reddy's can remain on the US market, the Federal Circuit has confirmed • Source: Shutterstock

Alvogen and Dr Reddy’s Laboratories can continue to market generic versions of Indivior’s Suboxone buprenorphine/naloxone sublingual films in the US after the Court of Appeals for the Federal Circuit upheld a district court’s finding in their favor on key patents protecting the opioid addiction treatment. But Teva remains barred from the market after the appeals panel confirmed that its version infringed a patent covering methods of making pharmaceutical films that runs until April 2024.

Both Alvogen and Reddy’s had launched generics of Suboxone earlier this year after the US Supreme Court denied the originator’s...

More from Legal & IP

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 
• By Urtė Fultinavičiūtė

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By Dean Rudge

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Alchem Fined Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

More from Generics Bulletin

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By Dave Wallace

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Three’s A Crowd? Celltrion Launches Denosumab In US

 
• By Dave Wallace

A third pair of Prolia and Xgeva rivals has now been launched in the US, with Celltrion throwing its hat into the ring after denosumab launches by Sandoz and Fresenius Kabi. But this is only the beginning for what is shaping up to be another highly competitive biosimilars market.

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By Dean Rudge

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.